A UNIQUE VISION ON MASTERING SIRP

A New Way to Change Lives

 

WE ARE TAKING A NOVEL APPROACH TO TARGETING SIRP

Our mastery of SIRP-directed biology is pointing the way toward breakthrough therapies for immunological diseases and cancer.

The Signal Regulatory Protein (SIRP) family of cell surface receptors consists of several proteins with differing roles across various immune cell types. Our immunology programs take advantage of the differential expression of SIRP proteins on leukocytes, which provides a means to deplete specific immune cell types. In our immuno-oncology platform, we leverage the SIRPα/CD47 immune checkpoint to promote targeted depletion of tumor cells.

We are embracing the endless possibilities of SIRP biology and

TRANSFORMING THE TREATMENT LANDSCAPE FOR PATIENTS MOST IN NEED.

Group 6031

SIRP-DIRECTED ANTIBODIES

IN DEVELOPMENT

Our novel monoclonal antibodies are designed to change the lives of patients with immunological diseases and cancer.

home-innovate-team

THE INNOVATIVE TEAM AT

ELECTRA THERAPEUTICS

Our team expands the possibilities of science to create transformative therapies for patients in need.

home-innovate-team

COLLECTIVELY EXPANDING

THE POSSIBILITIES

Electra Therapeutics is a part of a constellation of companies led by Star Therapeutics, which focuses on developing life-changing therapies for patients with rare diseases.